(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.00% ¥ 49.00
Live Chart Being Loaded With Signals
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg...
Stats | |
---|---|
Volumen de hoy | 530 600 |
Volumen promedio | 1.23M |
Capitalización de mercado | 10.67B |
EPS | ¥0 ( 2024-02-08 ) |
Próxima fecha de ganancias | ( ¥0 ) 2024-05-07 |
Last Dividend | ¥0 ( N/A ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -1.250 |
ATR14 | ¥0.577 (1.15%) |
Volumen Correlación
AnGes, Inc. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
AnGes, Inc. Correlación - Moneda/Commodity
AnGes, Inc. Finanzas
Annual | 2023 |
Ingresos: | ¥152.99M |
Beneficio Bruto: | ¥-3.07B (-2 003.65 %) |
EPS: | ¥-39.29 |
FY | 2023 |
Ingresos: | ¥152.99M |
Beneficio Bruto: | ¥-3.07B (-2 003.65 %) |
EPS: | ¥-39.29 |
FY | 2022 |
Ingresos: | ¥67.06M |
Beneficio Bruto: | ¥-2.92B (-4 354.66 %) |
EPS: | ¥-94.29 |
FY | 2021 |
Ingresos: | ¥64.15M |
Beneficio Bruto: | ¥7.43M (11.58 %) |
EPS: | ¥-92.86 |
Financial Reports:
No articles found.
AnGes, Inc.
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico